Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 24, Issue 9, Pages 2206-2223
Publisher
Oxford University Press (OUP)
Online
2013-08-06
DOI
10.1093/annonc/mdt303
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor positive node negative breast cancer
- (2013) J.A. Davidson et al. EUROPEAN JOURNAL OF CANCER
- A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study
- (2013) C.A. Drukker et al. INTERNATIONAL JOURNAL OF CANCER
- Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
- (2013) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial
- (2013) Aron Goldhirsch et al. LANCET
- Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial
- (2013) Viviana Galimberti et al. LANCET ONCOLOGY
- 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial
- (2013) Xavier Pivot et al. LANCET ONCOLOGY
- The Genomic Landscape of Breast Cancer as a Therapeutic Roadmap
- (2013) Matthew J. Ellis et al. Cancer Discovery
- EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer
- (2012) P. Dubsky et al. ANNALS OF ONCOLOGY
- Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole
- (2012) P. E. Goss et al. ANNALS OF ONCOLOGY
- The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use
- (2012) W. Eiermann et al. ANNALS OF ONCOLOGY
- Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
- (2012) R. Coleman et al. ANNALS OF ONCOLOGY
- Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen
- (2012) A. Prat et al. ANNALS OF ONCOLOGY
- Axillary Dissection Versus No Axillary Dissection in Older Patients With T1N0 Breast Cancer
- (2012) Gabriele Martelli et al. ANNALS OF SURGERY
- Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer
- (2012) Malek B Hannouf et al. BMC CANCER
- Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: Sentinel node vs Observation after axillary UltraSouND)
- (2012) Oreste Gentilini et al. BREAST
- Economic evaluation of the 70-gene prognosis-signature (MammaPrint®) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan
- (2012) Masahide Kondo et al. BREAST CANCER RESEARCH AND TREATMENT
- Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer
- (2012) Nathan W. D. Lamond et al. BREAST CANCER RESEARCH AND TREATMENT
- Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis
- (2012) Saroj Niraula et al. BREAST CANCER RESEARCH AND TREATMENT
- p53-Mediated Senescence Impairs the Apoptotic Response to Chemotherapy and Clinical Outcome in Breast Cancer
- (2012) James G. Jackson et al. CANCER CELL
- Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)
- (2012) N. Mavaddat et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial
- (2012) M. C. U. Cheang et al. CLINICAL CANCER RESEARCH
- Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer
- (2012) Shelby D. Reed et al. GENETICS IN MEDICINE
- Adherence to the mediterranean diet and risk of breast cancer in the European prospective investigation into cancer and nutrition cohort study
- (2012) G. Buckland et al. INTERNATIONAL JOURNAL OF CANCER
- Obesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 Trial
- (2012) Marianne Ewertz et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting Adjuvant Chemotherapy: A Good Idea That Needs to Be Proven!
- (2012) Daniel F. Hayes JOURNAL OF CLINICAL ONCOLOGY
- Suppression of Plasma Estrogen Levels by Letrozole and Anastrozole Is Related to Body Mass Index in Patients With Breast Cancer
- (2012) Elizabeth J. Folkerd et al. JOURNAL OF CLINICAL ONCOLOGY
- Is Adjuvant Chemotherapy Useful for Women With Luminal A Breast Cancer?
- (2012) Alan S. Coates et al. JOURNAL OF CLINICAL ONCOLOGY
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
- (2012) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Adoption of Gene Expression Profile Testing and Association With Use of Chemotherapy Among Women With Breast Cancer
- (2012) Michael J. Hassett et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Significance of Progesterone Receptor–Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer
- (2012) Aleix Prat et al. JOURNAL OF CLINICAL ONCOLOGY
- Age-Specific Incidence of Breast Cancer Subtypes: Understanding the Black–White Crossover
- (2012) Christina A. Clarke et al. JNCI-Journal of the National Cancer Institute
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
- (2012) Christina Davies et al. LANCET
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Estrogen receptor prevents p53-dependent apoptosis in breast cancer
- (2012) S. T. Bailey et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
- (2012) Ashish Juvekar et al. Cancer Discovery
- Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting
- (2012) J. U. Blohmer et al. JOURNAL OF MEDICAL ECONOMICS
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
- (2011) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Locoregional recurrence risk after lipofilling in breast cancer patients
- (2011) J. Y. Petit et al. ANNALS OF ONCOLOGY
- Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review
- (2011) Elisabeth Luporsi et al. BREAST CANCER RESEARCH AND TREATMENT
- Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer?
- (2011) Viviana Galimberti et al. BREAST CANCER RESEARCH AND TREATMENT
- Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer
- (2011) Ana P. Kiess et al. CANCER
- Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis
- (2011) Armando E. Giuliano JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- TP53 Status and Response to Treatment in Breast Cancers
- (2011) Mariana Varna et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis of the Prospective ABCSG-12 Trial
- (2011) Georg Pfeiler et al. JOURNAL OF CLINICAL ONCOLOGY
- Economic Evaluation of Genomic Test–Directed Chemotherapy for Early-Stage Lymph Node–Positive Breast Cancer
- (2011) Peter S. Hall et al. JNCI-Journal of the National Cancer Institute
- Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
- (2011) M. Dowsett et al. JNCI-Journal of the National Cancer Institute
- Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis
- (2011) Eitan Amir et al. JNCI-Journal of the National Cancer Institute
- Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial
- (2011) Michael Gnant et al. LANCET ONCOLOGY
- TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial
- (2011) Hervé Bonnefoi et al. LANCET ONCOLOGY
- Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs
- (2011) Thordur Oskarsson et al. NATURE MEDICINE
- Breast-Cancer Adjuvant Therapy with Zoledronic Acid
- (2011) Robert E. Coleman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association between breast cancer subtypes and response to neoadjuvant anastrozole
- (2011) Anita K. Dunbier et al. STEROIDS
- A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer
- (2010) T. O. Nielsen et al. CLINICAL CANCER RESEARCH
- Obesity and Hormone Therapy in Breast Cancer: An Unfinished Puzzle
- (2010) Pamela J. Goodwin et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC Trial
- (2010) Ivana Sestak et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer
- (2010) Timothy J. Whelan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost-Effectiveness Analysis of Recurrence Score-Guided Treatment Using a 21-Gene Assay in Early Breast Cancer
- (2010) D. T. Tsoi et al. ONCOLOGIST
- Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: Recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009)
- (2010) Csaba Polgár et al. RADIOTHERAPY AND ONCOLOGY
- Economic Implications of 21-Gene Breast Cancer Risk Assay from the Perspective of an Israeli-Managed Health-Care Organization
- (2010) Shmuel H. Klang et al. VALUE IN HEALTH
- The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer
- (2009) Marieke E. Straver et al. BREAST CANCER RESEARCH AND TREATMENT
- Accelerated Partial Breast Irradiation Consensus Statement From the American Society for Radiation Oncology (ASTRO)
- (2009) Benjamin D. Smith et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
- (2009) Joel S. Parker et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2009) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
- Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
- (2009) Maggie C. U. Cheang et al. JNCI-Journal of the National Cancer Institute
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
- (2009) Kathy S Albain et al. LANCET ONCOLOGY
- Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer
- (2009) Hyman B. Muss et al. NEW ENGLAND JOURNAL OF MEDICINE
- Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?
- (2008) M. M. Regan et al. ANNALS OF ONCOLOGY
- Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole
- (2008) Giuseppe Viale et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer
- (2008) Giuseppe Viale et al. JNCI-Journal of the National Cancer Institute
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started